Overview

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Watson Pharmaceuticals
Treatments:
Ferric Compounds
Ferric gluconate
Iron